April 10, 2018
Hummingbird Bioscience, a drug discovery and development company focused on novel cancer immuno-therapeutics, will present a poster “HMBD-002-V4, an Anti-VISTA Neutralizing Antibody, Displays Potent Anti-Tumor Efficacy in Combination with Anti-PD(L)1, Through Release of MDSC Mediated Immunosuppresion in the TME” at the American Association for Cancer Research Annual Meeting in Chicago taking place from 14-18 April, 2018.
HMBD-002-V4 is a novel anti-VISTA antibody developed using Hummingbird’s proprietary Rational Antibody Discovery platform to target and inhibit a predicted functional domain on the VISTA protein, while maintaining cross-reactivity to the murine and cyno versions of the protein allowing the antibody to be tested in animal models.
VISTA is a negative checkpoint regulator of the immune system and is highly expressed on Myeloid Derived Suppressor Cells (MDSCs). These cells are frequently upregulated in tumors following anti-PD(L)1 or anti-CTLA4 checkpoint therapy, leading to immune suppression and poor patient responses to therapy.
Treatment with HMBD-002-V4 in combination with anti-PD(L)1 therapy counteracts the expansion of MDSCs and remodels the immunosuppressive tumor microenvironment towards a pro-inflammatory environment, resulting in potent inhibition of tumor growth in a variety of syngeneic murine cancer models with MDSC infiltration.
The poster will be presented on Monday 16 April, 2018.
HMBD-002-V4 is wholly owned and developed by Hummingbird Bioscience.
For further information please email firstname.lastname@example.org
Hummingbird Bioscience is an innovative
biotechnology company, harnessing the potential of integrative biology to
discover and develop novel cancer immuno-therapeutics. We are focused on taking projects from
validated target to clinical proof of concept. Our data and model driven
integrative biology approach provide an unprecedented ability to understand and
manipulate the immune system – allowing us to 1) Identify the right targets and
mechanisms 2) Generate best in class antibodies against these targets 3)
Characterize the effect of our drug candidates on the tumor and immune system
at a molecular and cellular level, to better predict clinical outcomes of our
drugs. We have compelling pre-clinical
data for four potential first in class therapeutic programs focused on the most
exciting targets in oncology.